Comparison of effects of dalteparin and enoxaparin on hemostatic parameters and von Willebrand factor in patients with unstable angina pectoris or non-ST- segment elevation acute myocardial infarction

American Journal of Cardiology

Volumn 89, Issue 5, 2002, Pages 589-592

  Hödl, Ronald ^a   Huber, Kurt ^b   Kraxner, Wilfried ^a   Nikfardjam, Mariam ^b   Schumacher, Martin ^a   Fruhwald, Friedrich M ^a   Zorn, Gerlinde ^b   Wonisch, Manfred ^a   Klein, Werner ^a  

^a UNIVERSITY OF GRAZ   (Austria)

^b UNIVERSITY OF VIENNA   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTIGEN; CREATINE KINASE MB; DALTEPARIN; ENOXAPARIN; LOW MOLECULAR WEIGHT HEPARIN; PLASMINOGEN ACTIVATOR INHIBITOR 1; PROTHROMBIN; THROMBIN; TROPONIN; VON WILLEBRAND FACTOR;

ACUTE HEART INFARCTION; AUSTRIA; BLEEDING; BLOOD SAMPLING; CALCULATION; CLINICAL TRIAL; DRUG EFFECT; ELECTROCARDIOGRAPHY; HEMOSTASIS; HUMAN; LABORATORY TEST; MORTALITY; PRIORITY JOURNAL; PROFESSIONAL STANDARD; REVIEW; ST SEGMENT DEPRESSION; ST SEGMENT ELEVATION; STATISTICAL ANALYSIS; T WAVE; THORAX PAIN; TREATMENT OUTCOME; UNSTABLE ANGINA PECTORIS;

EID: 0036499045     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9149(01)02300-1     Document Type: Article

References (13)

1. Low-molecular weight heparin reduces the generation and activity of thrombin in unstable coronary artery disease
2. A rise of troponin and/or von Willebrand factor over the first 48 hours is associated with a poorer 1-year outcome in unstable angina patients
3. Effects of various anticoagulant treatments on von Willebrand factor release in unstable angina
4. Comparison of the pharmacokinetic profiles of three low molecular mass heparins - Dalteparin, enoxaparin and nadroparin - Administered subcutaneously in healthy volunteers (doses for prevention of thromboembolism)
5. ®): Pharmacokinetics after intravenous and subcutaneous administration
6. The antithrombotic activity and pharmacokinetics of enoxaparin, a low molecular weight heparin, in humans given single subcutaneous doses of 20 to 80 mg
7. Concentration of endogenous tPA antigen in coronary artery disease: Relation to thrombotic events, aspirin treatment, hyperlipidemia, and multivessel disease
8. Alterations of coagulation and fibrinolytic and kallikrein-kinin systems in the acute and postacute phases in patients with unstable angina pectoris
9. Sandwich ELISA for t-PA antigen employing a monoclonal antibody
10. Hyperthermia stimulates plasminogen activator inhibitor type-1 expression in human umbilical vein endothelial cells in vitro
11. Limitation of vWf meta-analysis in LMWH comparison
12. A comparison of low-molecular-weight heparin with unfractionated heparin for unstable coronary artery disease. Efficacy and safety of subcutaneous enoxaparin in non-q-wave coronary events study group
13. Enoxaparin prevents death and cardiac ischaemic events in unstable angina/non-Q-wave myocardial infarction. Results of the Thrombolysis In Myocardial Infarction (TIMI) 11B trial